S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Laser breakthrough could send stock soaring 2,467% (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Laser breakthrough could send stock soaring 2,467% (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Laser breakthrough could send stock soaring 2,467% (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Laser breakthrough could send stock soaring 2,467% (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

$1.93
+0.43 (+28.67%)
(As of 02/23/2024 08:54 PM ET)
Today's Range
$1.49
$2.00
50-Day Range
$0.73
$2.78
52-Week Range
$0.66
$10.50
Volume
215,100 shs
Average Volume
323,336 shs
Market Capitalization
$30.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00

Alaunos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
2,231.6% Upside
$45.00 Price Target
Short Interest
Healthy
11.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.64 out of 5 stars

Medical Sector

675th out of 936 stocks

Pharmaceutical Preparations Industry

306th out of 422 stocks


TCRT stock logo

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

TCRT Stock Price History

TCRT Stock News Headlines

The #1 Energy Passive Income Investment for 2023
It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.
Werewolf Therapeutics Inc (HOWL)
Recap: Alaunos Therapeutics Q3 Earnings
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
The #1 Energy Passive Income Investment for 2023
It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.
Alaunos Therapeutics Inc TCRT
8-K: Alaunos Therapeutics, Inc.
See More Headlines
Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
2/25/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRT
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.00
High Stock Price Target
$45.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+2,231.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-37,730,000.00
Pretax Margin
-243,039.98%

Debt

Sales & Book Value

Annual Sales
$2.92 million
Book Value
$2.67 per share

Miscellaneous

Free Float
15,058,000
Market Cap
$30.98 million
Optionable
Optionable
Beta
-0.23
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














TCRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Alaunos Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares.
View TCRT analyst ratings
or view top-rated stocks.

What is Alaunos Therapeutics' stock price target for 2024?

3 brokerages have issued 12 month price targets for Alaunos Therapeutics' shares. Their TCRT share price targets range from $45.00 to $45.00. On average, they expect the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 2,231.6% from the stock's current price.
View analysts price targets for TCRT
or view top-rated stocks among Wall Street analysts.

How have TCRT shares performed in 2024?

Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of the year. Since then, TCRT shares have increased by 82.0% and is now trading at $1.93.
View the best growth stocks for 2024 here
.

Are investors shorting Alaunos Therapeutics?

Alaunos Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 1,710,000 shares, a decline of 7.1% from the January 15th total of 1,840,000 shares. Based on an average daily trading volume, of 436,600 shares, the short-interest ratio is presently 3.9 days. Currently, 11.2% of the shares of the stock are short sold.
View Alaunos Therapeutics' Short Interest
.

When is Alaunos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our TCRT earnings forecast
.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.15.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics's stock reverse split on the morning of Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Alaunos Therapeutics' major shareholders?

Alaunos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include MSD Partners L.P. (94.40%), Commerce Bank (2.72%), Magnolia Capital Advisors LLC (0.17%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma.
View institutional ownership trends
.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRT) was last updated on 2/26/2024 by MarketBeat.com Staff